SunTrust starts Matinas BioPharma with Buy rating, $3 price target » 16:2201/2301/23/20
SunTrust analyst Gregg…
SunTrust analyst Gregg Gilbert initiated coverage of Matinas BioPharma with a Buy rating and $3 price target. The company's lead asset MAT9001 is targeting the omega-3 market, which the analyst believes is large and poised for strong growth. While a few years from market, MAT9001 could "carve out a nice slice of the omega-3 market given its unique characteristics," Gilbert tells investors in a research note.
Matinas BioPharma initiated with a Buy at SunTrust » 16:1001/2301/23/20
SunTrust initiated coverage of Matinas BioPharma with a Buy rating and $3 price target.
|Over a week ago|
Fly Intel: Pre-market Movers » 09:0001/1001/10/20
GRUB, SRNE, DERM, LLY, NLOK, ISRG, SNX, KBH, PTLA, MTNB, SIX
HIGHER: Sorrento Therapeutics (SRNE), up 47% after it received a non-binding proposal from a private equity fund to acquire a majority or all of the issued and outstanding shares of the company for up to $7.00 per share... Dermira (DERM), up 4% after entering a definitive agreement for Eli Lilly (LLY) to acquire the company for $18.75 per share, or approximately $1.1B, in an all-cash transaction... Intuitive Surgical (ISRG), up 3% after reporting preliminary Q4 revenue above estimates... NortonLifeLock (NLOK), up 2% after its board declared a special, one-time cash dividend of $12 per share of common stock. UP AFTER EARNINGS: Synnex (SNX), up 8%. DOWN AFTER EARNINGS: KB Home (KBH), down 2%. ALSO LOWER: GrubHub (GRUB), down 8% after Bloomberg reported that the company said it is not running a sale process... Portola Pharmaceuticals (PTLA), down 40% after announcing preliminary Andexx revenue for Q4... Matinas BioPharma (MTNB), down 19% after a common stock offering... Six Flags (SIX), down 15% after Wells Fargo analyst Timothy Conder downgraded shares to Equal Weight from Overweight with a price target of $42, down from $49.
Matinas BioPharma 32.2M share Spot Secondary priced at $1.55 » 08:2901/1001/10/20
The deal range was…
The deal range was $1.50-$1.60. Piper Sandler acted as lead book running manager for the offering.
Matinas BioPharma announces common stock offering » 16:1601/0901/09/20
Matinas BioPharma Holdings announced that it has commenced an underwritten public offering of its common stock. Matinas BioPharma anticipates using the net proceeds from the offering for ongoing development activities for its product candidates, primarily MAT9001, and for working capital and other general corporate purposes. Piper Sandler & Co. is acting as the sole lead active bookrunner for the offering. SunTrust Robinson Humphrey is also acting as a bookrunner for the offering.
Matinas BioPharma initiated with a Buy at Aegis » 13:1601/0901/09/20
Aegis analyst Nathan…
Aegis analyst Nathan Weinstein initiated coverage of Matinas BioPharma with a Buy rating and $3.50 price target.
|Over a month ago|
Matinas BioPharma announces feasibility evaluation with Genentech » 07:0912/1212/12/19
Matinas BioPharma Holdings (MTNB) announced that it has entered into a feasibility evaluation with Genentech, a member of the Roche Group (RHHBY). This feasibility evaluation will involve the development of oral formulations using Matinas' lipid nano-crystal platform delivery technology, which enables the development of a wide range of difficult-to-deliver molecules. Matinas' LNC platform delivery technology offers an intracellular drug delivery solution with potential advantages across a broad range of therapeutics. The Company has demonstrated in preclinical animal models the ability to formulate and thereby re-design a wide variety of molecules and drugs which, require delivery technology to improve the stability of molecules inside and outside of the body; could benefit from efficient delivery and cellular uptake by target cells; are currently only available in intravenous formulations or otherwise experience significant toxicity-related adverse events.
Amarin AdCom for Vascepa a positive for Omega-3 participant Matinas, says BTIG » 09:5211/1411/14/19
BTIG analyst Robert…
BTIG analyst Robert Hazlett said that briefing documents for the advisory committee to discuss Amarin's (AMRN) Vascepa "appear generally benign" and largely supportive of the Omega-3 class, which he views as a positive for all Omega-3 participants, including Matinas BioPharma (MTNB), which is pre-screening patients for its additional upcoming head-to-head study of MAT9001 versus Vascepa in high triglyceride patients. He believes today's FDA advisory panel meeting should provide some clarity for the market opportunity of Omega-3s for cardiovascular risk reduction and keeps a Buy rating and $5 price target on Matinas shares.
Matinas BioPharma reports Q3 EPS (3c), consensus (3c) » 06:3911/1311/13/19
Reports Q3 revenue $0,…
Reports Q3 revenue $0, consensus $10K. "I am extremely pleased with the progress we made in the third quarter, positioning the Company to commence two important studies for our lead assets, MAT9001 and MAT2203," commented CEO Jerome Jabbour. "With respect to MAT9001, we began pre-screening patients in September for our confirmatory head to head ENHANCE-IT study vs. Vascepa, and remain on track to start dosing patients in early 2020. This is an exciting time for the omega-3 class as there are multiple upcoming catalysts that could help validate the blockbuster potential of prescription-only omega-3 therapy. We look forward to reporting data from the ENHANCE-IT trial in 4Q20, and continue to believe that MAT9001 has the potential to become the best-in-class prescription-only omega-3 product."
|Over a quarter ago|
Matinas BioPharma management to meet with Maxim » 04:5510/1510/15/19
Meeting to be held in the…
Meeting to be held in the New York on October 15 hosted by Maxim.